COMBINATION PRODUCT FOR RELIEVING SYMPTOMS RELATED TO UPPER RESPIRATORY TRACT INFECTIONS

Abstract

The present invention relates to a combination product comprising, as active substances, at least zinc, eucalyptus, and erysimum, or a bioequivalent compound thereof, to help relieve symptoms associated with upper respiratory tract infections. The invention also relates to the use of a combination product as defined above for the treatment of symptoms associated with upper respiratory tract infections.

Description

The main bacteria responsible for sinus superinfections are: Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis, Staphylococcus aureus. Fungi: Aspergillus Sinusitis can be of two types: Acute: caused in most cases by a viral infection such as a cold, it heals in 7 to 12 days. It can also be caused by allergies or dental abscesses. Chronic sinusitis can result from poorly treated infections and is often exacerbated by anatomical or allergic factors. Sinusitis is considered chronic when it lasts longer than two weeks and up to four to eight weeks. However, acute sinusitis can be considered chronic if it recurs two to four times within the same year. To relieve the symptoms of upper respiratory tract infections, various products are available on the market. These products generally contain paracetamol, pseudoephedrine, chlorphenamine, and diphenhydramine. Such products are marketed by URGO Laboratories under the brand name HUMEX® Cold Day and Night, by UPSA under the brand name FERVEX® Cold Day and Night, and by Johnson & Johnson under the brand name ACTIFED® Cold Day and Night. Due to the presence of active ingredients such as paracetamol, pseudoephedrine, chlorphenamine, and diphenhydramine, these formulations are not suitable for everyone.Indeed, these products should not be used in the following cases: liver failure; risk of closed-angle glaucoma; risk of urinary blockage (prostate adenoma); high blood pressure not controlled by specific treatment; severe coronary insufficiency; history of seizures; history of stroke; in combination with a non-selective MAOI antidepressant or for at least 15 days after taking it; in combination with another decongestant vasoconstrictor or a vasoconstrictor containing one of the following substances: bromocriptine, pergolide, lisuride, cabergoline, ergotamine or dihydroergotamine; children under 15 years of age; breastfeeding. Furthermore, consumers are increasingly opting for natural solutions and are reluctant to use active ingredients such as those described above. Among the existing natural solutions, one can cite as an example the product Arkopharma Duoflash® Respiratory Comfort which contains sunflower oil, essential oil of Ravintsara leaf (Cinnamomum Camphora), essential oil of flowering aerial part of thyme with Thymol (Thymus Vulgaris), extract of Eucalyptus leaf (Eucalyptus Globulus), and extract of Pelargonium root (Pelargonium Sidoides). The Efirub® product from Laboratoires les 3 Chênes contains echinacea extract, N-acetyl-L-cysteine, Andrographis extract, Astragalus extract, thyme extract, grapefruit seed extract, vitamin C, white willow extract, uncaria tomantosa extract, licorice extract, black elderberry extract, and zinc. We can also mention the product Actirub®, marketed by Laboratoire Santé Verte, which contains dry extract of echinacea (Echinacea purpurea) standardized to 4% echinacosides, dry extract of andrographis (Angrographis paniculata) standardized to 6% andrographolides, dry extract of astragalus (Astragalus membranaceus) standardized to 16% polysaccharides, N-acetylcysteine, vitamin C, dry extract of mullein (Verbascum thapsus), dry extract of thyme (Thymus vulgaris), dry extract of white willow (Salix alba) standardized to 25% salicin, dry extract of feverfew (Tanacetum parthenium) standardized to 0.5% parthenolides, and dry extract of black elderberry (Sambucus nigra) standardized to 4.5% rutin, zinc. None of the products offered contain the association that is the subject of the present invention. The Applicant has developed, and this is the subject of the present invention, a combination product comprising, as active substances, at least zinc, eucalyptus and erysimum or a bioequivalent compound of these to help relieve symptoms related to upper respiratory tract infections. "Relieving symptoms related to upper respiratory tract infections" in the context of the present invention means a product that soothes the throat, provides energy for the day, clears the upper respiratory tract, particularly the nose, by providing a feeling of freshness, and also facilitates falling asleep at bedtime. Such a product therefore makes it possible to relieve the symptoms associated with upper respiratory tract infections using products of natural origin and to treat a larger number of people. The product according to the present invention also has the advantage of preferably containing no artificial colorings or allergens and of preferably being lactose-free or gluten-free. The product of the present invention has a dosage form suitable for adults, preferably in the form of a tablet to be sucked or swallowed. The product according to the present invention, although containing products of natural origin, has a pleasant taste and smell. SUMMARY OF THE INVENTION The present invention relates to a combination product, comprising as active substances, at least zinc, eucalyptus and erysimum or a bioequivalent compound of eucalyptus and erysimum to help relieve symptoms associated with upper respiratory tract infections. The present invention also relates to a combination product, comprising as active substances at least zinc, eucalyptus and erysimum or a bioequivalent compound of eucalyptus and erysimum for its use in the treatment of symptoms related to upper respiratory tract infections. In certain embodiments, the combination product according to the invention comprises, in addition to zinc, eucalyptus and erysimum, as active substances: (i) Plants or plant extracts, such as, for example, the poppy (ii) Vitamins and minerals, such as, for example, vitamin C, (iii) Propolis In certain embodiments, the combination product according to the invention is in the form of a single composition containing at least: -3 to 15%, preferably 6 to 10%, of dry eucalyptus extract -3 to 10%, preferably 4 to 8% dry extracts of erysimum -0.01 to 0.2%, preferably 0.05 to 0.1% zinc as a percentage by weight relative to the total weight of the composition in a physiologically acceptable medium. In certain embodiments, the combination product of the invention is characterized in that eucalyptus and erysimum are presented in the form of plant extracts in a tablet comprising: 3 to 15%, preferably 6 to 10%, of dry eucalyptus extract 3 to 10%, preferably 4 to 8% dry extracts of erysimum 0.01 to 0.2%, preferably 0.05 to 0.1% zinc as a percentage by weight relative to the total weight of the composition In another embodiment, the combination product according to the invention is characterized in that it is in the form of a single composition containing at least: -3 to 15%, preferably 6 to 10%, of dry eucalyptus extract -3 to 10%, preferably 4 to 8% dry extracts of erysimum -0.01 to 0.2%, preferably 0.05 to 0.1% zinc -1 to 10%, preferably 2 to 5% dry poppy extract as a percentage by weight relative to the total weight of the composition in a physiologically acceptable medium. In certain embodiments, the combination product of the invention is characterized in that the tablet comprises, according to a first alternative: 3 to 15%, preferably 6 to 10%, of dry eucalyptus extract 3 to 10%, preferably 4 to 8% dry extracts of erysimum 0.01 to 0.2%, preferably 0.05 to 0.1% zinc 1 to 10%, preferably 2 to 5% dry poppy extract as a percentage by weight relative to the total weight of the composition In this alternative, the composition will preferably be taken before the sleep phase of the subject presenting with an upper respiratory tract infection. According to an alternative, the combination product according to the invention is characterized in that it is in the form of a single composition containing at least: -3 to 15%, preferably 6 to 10%, of dry eucalyptus extract -3 to 10%, preferably 4 to 8% dry extracts of erysimum -0.01 to 0.2%, preferably 0.05 to 0.1% zinc -0.01 to 2%, preferably 0.05 to 1% propolis -1 to 20%, preferably 5 to 10% vitamin C as a percentage by weight relative to the total weight of the composition in a physiologically acceptable medium. In certain embodiments, the combination product of the invention is characterized in that the tablet comprises, according to a second alternative: 3 to 15%, preferably 6 to 10%, of dry eucalyptus extract 3 to 10%, preferably 4 to 8% dry extracts of erysimum 0.01 to 0.2%, preferably 0.05 to 0.1% zinc 0.01 to 2%, preferably 0.05 to 1% propolis 1 to 20%, preferably 5 to 10% vitamin C as a percentage by weight relative to the total weight of the composition In this alternative, the composition will preferably be taken during the "active" phase, that is, at least 4 hours before the sleep phase of the subject with an upper respiratory tract infection. In certain embodiments of the invention, the combination product according to the invention may be in the form of a single (or combined) composition containing at least the following active substances: In certain embodiments of the invention, the combination product according to the invention may be in the form of a single (or combined) composition containing at least the following active substances: (i) zinc, (ii) eucalyptus, (iii) of erysimum, (iv) of the poppy (v) of propolis (vi) of vitamin C in a physiologically acceptable environment. According to a particular embodiment of the invention, the combination product is characterized in that the active ingredients (i), (ii), (iii), (iv), (v), and (vi), or a bioequivalent compound thereof, are in a medium suitable for oral administration. Preferably, the suitable medium is a solid medium. Preferably, the combination product is in tablet form. Eucalyptus, erysimum, and poppy may be present as ingredients (ii), (iii) or (iv) in a combination product of the invention in a more or less purified form, in particular in the form of a plant extract. The various embodiments of the invention are particularly described in the detailed description below. These embodiments can be considered separately or in combination with each other. DETAILED DESCRIPTION OF THE INVENTION: In the present invention, the applicant has demonstrated that the combination of zinc, eucalyptus and erysimum has a synergistic effect to help relieve symptoms related to upper respiratory tract infections. By synergistic effect, it is understood according to the present invention that the combination of zinc, eucalyptus, and erysimum has an effect on the relief of symptoms related to upper respiratory tract infections, during treatment which is superior to the cumulative effects of a treatment (a) including the administration of zinc, not associated with eucalyptus, erysimum, and conversely of a treatment (b) including the administration of eucalyptus, not associated with zinc and erysimum or of a treatment (c) including the administration of erysimum, not associated with zinc and eucalyptus. Eucalyptus Native to Australia, the genus Eucalyptus has given rise to more than 600 species, ranging from simple shrubs to very large trees. Several tree species have long been cultivated in the Mediterranean basin and throughout subtropical regions, both in the East and the West. European aromatherapy primarily uses the essential oil of four species of eucalyptus. • Lemon eucalyptus (E. citriodord). Preferred for topical applications (arthritis, tendinitis, itching, mosquito repellent, etc.). • Eucalyptus mentholata (E. dives). Preferred for respiratory ailments, but the use of its essential oil is not recommended for children under 6 years of age and for pregnant or breastfeeding women. • Eucalyptus radiata (E. radiata). Better tolerated by mucous membranes and skin; well-suited for children. Not recommended during the first three months of pregnancy. • Eucalyptus polybractea CT cryptone. Preferred for parasitic infections (especially tropical diseases) and for viral gynecological or urinary tract infections. The essential oil is not recommended for children under 6 years of age or for pregnant or breastfeeding women. Researchers believe that the medicinal properties of eucalyptus are primarily attributable to the eucalyptol (also called 1,8-cineole) contained in its leaves. This is why it is generally agreed that, to be effective, the essential oil must contain 70% to 85% Approved use: The European Commission has approved the use of the leaves (internal use) and the essential oil (internal and external use) of Eucalyptus globulus, to treat inflammation of the respiratory tract. The World Health Organization recognizes the traditional use of eucalyptus (E. globulus) leaves to relieve fever and symptoms of asthma, inflammation of the respiratory tract, bronchi or throat. The composition according to the present invention comprises 3 to 15% preferably 6 to 10% of dry eucalyptus extracts as a percentage by weight relative to the total weight of the composition. Erysimum Wallflowers (Erysimum) is a genus of dicotyledonous plants in the Brassicaceae family. This genus includes wallflowers, which comprise both cultivated ornamental species and various wild forms. Wallflowers have pain-relieving effects and active ingredients similar to those of promethazine. With expectorant properties, wallflower leaves can soothe coughs and laryngitis. They are therefore recommended for hoarseness. Since these same leaves are mucolytic, they can also facilitate the expulsion of mucus. They also help prevent scurvy and stimulate the entire body. The flowering tops of this plant have the same properties as the leaves. The composition according to the present invention comprises 3 to 10%, preferably 4 to 8%, of dry extracts of erysimum as a percentage by weight relative to the total weight of the composition. Zinc Zinc is a trace element essential in small doses for animal and human life. In very small quantities, zinc in its absorbable form is an important trace element, essential for plant and animal organisms. When properly absorbed by organisms, it activates enzymes, influences growth, and promotes biochemical reactions and controls at the level of the lung surfaces. The human body contains 2 to 4 grams. Daily requirements can be estimated at a minimum of 15 mg for a normal man, and up to twice as much for a breastfeeding woman. Zinc is found in various yeasts (up to 100 mg per kilogram) and in beef (from 50 mg to 120 mg per kilogram), but also in a multitude of commercially available foods. Even a slight deficiency has an impact on certain functions, including the immune system responsible for defending against certain infections. The composition according to the present invention comprises from 0.01 to 0.2%, preferably 0.05 to 0.1% of zinc as a percentage by weight relative to the total weight of the composition. The poppy The poppy (Papaver rhoeas) is a species of dicotyledonous plant in the family Papaveraceae, native to Eurasia. It is an annual herbaceous plant, very abundant in freshly disturbed soil from spring onwards, distinguished by the red color of its flowers and by the fact that it often forms large, colorful carpets visible from afar. It belongs to the group of so-called cornfield weeds because it has been associated with agriculture since ancient times, thanks to its life cycle adapted to cereal crops, with flowering and seed production occurring before harvest. Like all poppies, the common poppy has narcotic effects due to the alkaloids it contains. In herbal medicine, its dried petals, which turn a deep red color when dried, are used to make herbal teas. Its soothing effects are felt by adults, but especially by young children (poppy was once mixed into children's porridge to help them sleep). Thanks to its emollient, mildly sedative, and cough-relieving properties, the poppy is a soothing remedy for coughs and throat irritations. It is then used in the form of lozenges. The composition according to the present invention comprises 1 to 10%, preferably 2 to 5% of dry poppy extracts as a percentage by weight relative to the total weight of the composition. Propolis Propolis refers both to a resinous substance produced by certain plants and to a complex material made by bees from this plant resin and wax. Plant propolis refers to a series of resinous, gummy and balsamic substances found on plants. The main tree species producing propolis are conifers (bark of pines, firs, spruces) and the buds of several species of alder, willow, birch, plum, ash, oak and elm, poplar (which seems to be the most important source) and horse chestnut. Bee propolis is a complex made by the bee from its secretions and the plant propolis it has collected. The propolis collected from the hive is generally composed of: Resins and balms: 50 to 55% wax: 30 to 40% volatile or essential oils: 5 to 10% pollen: 5% Miscellaneous materials: 5% This propolis also contains many other elements such as organic acids, numerous flavonoids, trace elements, and many vitamins. It also contains parabens, whose antibacterial and antifungal properties help fight pathogens in the hive. In the beehive, propolis has multiple uses. It acts as a mortar to seal cracks and gaps, to waterproof against moisture and mold growth, to reinforce honeycombs or damaged parts of the hive, and to protect the colony by reducing the hive entrance. It also serves as a sanitizing varnish when applied in a thin layer. A layer inside the cells before the queen lays her eggs, or to smooth the inner walls of the hive. It is also used to mummify dead intruding animals (rats and mice, for example) that are too large to be removed by the bees, thus preventing their decomposition. Raw propolis or propolis in tincture form is an anti-infective agent (antifungal, antiseptic, antibiotic). It also has anesthetic, healing, and anti-inflammatory properties and increases cellular metabolism. For internal use, it would be used in the form of a mother tincture or in the form of a dry extract in otolaryngology against loss of voice, hoarseness, tonsillitis, sore throats, coughs, colds, bronchitis, pharyngitis, otitis and sinusitis. In the context of the present invention, propolis is a complex material produced by bees from plant propolis and wax The composition according to the present invention comprises 0.01 to 2%, preferably 0.05 to 1% of propolis as a percentage by weight relative to the total weight of the composition. Vitamin C Vitamin C is a water-soluble vitamin sensitive to heat and light that plays an important role in the metabolism of humans and many other mammals. Chemically speaking, it is L-ascorbic acid, one of the stereoisomers of ascorbic acid, and its salts, the ascorbates. The most common are sodium ascorbate and calcium ascorbate. Vitamin C is an enzymatic cofactor involved in several physiological reactions (hydroxylation). It is required for the synthesis of collagen and red blood cells and contributes to the immune system. It also plays a role in iron metabolism by promoting iron absorption; therefore, its use is not recommended in patients with iron overload, particularly those with hemochromatosis. In its oxidized form (dehydroascorbic acid), it crosses the blood-brain barrier to reach the brain and several organs with high concentrations of vitamin C. This vitamin is widely used for self-medication for the common cold. It appears to shorten the duration of symptoms and improve them in adults. The composition according to the present invention comprises from 1 to 20%, preferably from 5 to 10% of vitamin C as a percentage by weight relative to the total weight of the composition. Physiologically acceptable environment A physiologically acceptable medium is one that has no toxic or harmful effects under the conditions of use and is inert with respect to the active ingredients of the combination product. Such a medium may, for example, include various adjuvants depending on its therapeutic or cosmetic purpose, such as, but not limited to, flavorings, colorants, fillers, preservatives, diluents, wetting or suspending agents, etc. Such media may also allow for the immediate, modified, or delayed release of one or more of the active ingredients. The physiologically acceptable medium may consist of water, fruit puree and / or juice, texturizers, emulsifiers, colors, preservatives, flavors, sugar or sugars. By "fruit puree and / or juice" we mean a preparation more or less liquid, in particular depending on the nature of the fruit and / or the fineness of the grinding, prepared by grinding, pressing or other extraction process of one or more fruits and possibly concentration of the resulting pulp and / or separation (in particular filtration) of the seeds, achenes and / or all or part of the pulp, and / or flash pasteurization. Fruits can be chosen from: apple, banana, strawberry, peach, raspberry, blackberry, mango, kiwi, blueberry, blackcurrant, redcurrant, orange, cherry, fig, pear, apricot, coconut, passion fruit, guava, papaya, melon, lychee, pineapple, lemon, mandarin, mirabelle plum, grapefruit, grape, rhubarb and their mixtures, without this list being exhaustive. Texturizers are compounds that modify the texture of the products in which they are incorporated. Examples of texturizers include: guar and locust bean gums; gum arabic, xanthan gum, and gellan gum; carrageenan; starches (native or modified); microcrystalline cellulose; gelatin; pectin; and alginates (E400 to E405). Agar-agar; and mixtures thereof. The term "emulsifiers" refers to amphiphilic compounds characterized by their HLB (Hydrophile Lipophilic Balance) value, particularly those capable of stabilizing oil-in-water emulsions (especially useful when adding, for example, fat-soluble active ingredients such as fat-soluble vitamins). Examples of food emulsifiers include lecithin and its derivatives, found notably in egg yolks; mono- and diglycerides of fatty acids; and polysorbate 80. The term "colorants" refers to compounds of natural or synthetic origin capable of imparting color to a product. Examples of food colorings are known in Europe under the codes E100 to E180. The term "preservatives" refers to compounds that inhibit the growth of microorganisms, particularly yeasts and / or molds and / or bacteria, especially Staphylococcus aureus, in the composition. Examples of food preservatives include sorbic acid and its salts (E200 to E203); benzoic acid and its salts (E210 to E219); sulfites and their derivatives (E220 to E228); natamycin; nisin; and mixtures thereof. Preferably, the composition according to the invention does not contain any preservatives. The term "flavorings" refers to compounds of natural or synthetic origin that can, on their own, alter the taste of the composition. Examples of flavorings include apricot, pineapple, banana, blackcurrant, cherry, lemon, lime, strawberry, raspberry, passion fruit, mandarin, mint, orange, pistachio, pear, licorice, rose, anise, blueberry, cinnamon, ginger, grapefruit, apple, kiwi, lychee, melon, coconut, peach, redcurrant, guava, grenadine, mango, blackberry, papaya, tea, vanillin, natural vanilla extract, essential oils, and mixtures thereof. For the purposes of this invention, "sugar" or "sugars" means any sweetening carbohydrate, preferably glucose syrup, sucrose, glucose, fructose, invert sugar, honey, maltose, polyol, or mixtures thereof. In the context of this invention, the sugar used is a polyol, preferably sorbitol. Additional asset(s) Any additional active ingredient with nutritional value and / or that helps relieve symptoms associated with upper respiratory tract infections may also be added to the combination products of the invention. The combination product may include, for example For example, vitamins, mineral salts, essential amino acids, essential fatty acids, trace elements, various plant extracts, fibers, antioxidants, flavonoids. Advantageously, such an additional active ingredient can be intended to enhance the desired effect as described above. Of course, a person skilled in the art will take care to choose the additional assets and their quantity in such a way that the advantageous properties of the composition according to the invention are not, or substantially not, altered by the envisaged addition. Examples of additional usable assets include: - Water-soluble and fat-soluble vitamins. Examples of water-soluble vitamins present in the syrupy product prepared according to the invention include: vitamin B1 (thiamine), vitamin B2 (riboflavin), vitamin B3 (nicotinic acid), also known as vitamin PP (Pellagra Preventive), vitamin B5 (pantothenic acid), vitamin B6 (pyridoxine), vitamin B8 or H (biotin), vitamin B9 (folic acid), and vitamin B12 (cobalamin). Examples of fat-soluble vitamins present in the syrupy product prepared according to the invention include: vitamin A (retinol), vitamin D3 (cholecalciferol), vitamin E (mixture of tocopherols and tocotrienols), and vitamin K (phylloquinone). - Antioxidants, such as curcuminoids; carotenoids, particularly those selected from beta-carotene, astaxanthin, zeaxanthin, lutein, or compounds containing them such as goji berries; polyphenol compounds, flavonoids such as catechins; proanthocyanidins, anthocyanins, OPCs (oligomeric procyanidins); ubiquinones; coffee extracts containing polyphenols and / or diterpenes; chicory extracts; ginkgo biloba extracts; grape extracts rich in proanthocyanidins; chili pepper extracts; soy extracts; cocoa; pomegranate; Emblica; Coenzyme Q10; selenium, - minerals, such as magnesium, calcium, copper, iron, iodine, manganese, selenium, chromium (III), - amino acids, particularly sulfur-containing amino acids, such as glutathione precursors, selenium amino acids, and citrulline, -phytosterols, resveratrol, hesperidin, neohesperidin, orthosilicic acid, monomethylsilanetriol, and mixtures thereof. 5. Preferably, a combination product according to the invention is administered orally. Suitable oral dosage forms include, for example, tablets, capsules, lozenges, powders, granules, lyophilized powders, oral solutions, and syrups. Tablets, powders, granules, lyophilized powders, oral solutions, and syrups constitute the currently preferred pharmaceutical form suitable for oral administration. 10. In the case of preparing a solid composition in tablet form, the main active ingredients (i), (ii), (iii), (iv), (v), or (vi) may, for example, be mixed with a physiologically acceptable vehicle such as gelatin, starch, magnesium stearate, calcium stearate, talc, acacia gum, or similar substances. The tablets can be of various types, immediate release, controlled or delayed release and possibly in effervescent or orodispersible form. A tablet preparation is obtained by mixing the active ingredient (i), (ii), (iii), (iv), (v) or (vi) in powder form. Example 1: Composition according to the invention (Table 1): Product Name Unit Quantity (mg) Percentage (% of total composition weight) Eucalyptus (dry extract) 66.667 8.89 Erysimum (dry extract) 41.667 5.56 Zinc Oxide 0.624 0.08 Natural Lemon Flavoring 16 2.13 Honey Powder 6 0.80 Poppy (dry extract) 22.4 2.99 Masking Agent: Bitter masking flavoring, Kerry 20 2.67 Sorbitol 562.642 75.02 Calcium Stearate 14 1.87 750 100 This composition is obtained by mixing the various components according to the processes classically used for this type of preparation. The composition is then preferably in tablet form. This tablet will preferably be taken by subjects with an upper respiratory tract infection before sleep (at bedtime). Example 2: Composition according to the invention (Table 2): Product Name Unit Quantity in mg Percentage (as a % of the total weight of the composition) Layer 1 Eucalyptus 66.667 8.60 Erysimum 41.667 5.38 Ascorbic Acid 44.11 5.69 Propolis 6.25 0.81 Mint Eucalyptus Flavor 20 2.58 Sorbitol 286.306 36.94 Calcium Stearate 10 1.29 0.00 Layer 2 0.00 Mint Flavor 20 2.58 Tea Flavor 20 2.58 Zinc Oxide 0.624 0.08 Sorbitol 252.376 32.56 Calcium Stearate 7 0.90 775 100.00 This composition is obtained by mixing the various components according to the processes classically used for this type of preparation. The composition is then preferably formulated as a bilayer tablet. This tablet will preferably be taken by the patient with an upper respiratory tract infection during the "active" phase; ideally, the patient will take two tablets during this "active" phase. Example 3: Perception survey of tablets based on examples 1 and 2 10 A panel of 60 people (men and women) over 18 years of age tested the tablets according to examples 1 and 2. These people had to comment on the smell, taste and perceived immediate effectiveness. Assessing the smell of the tablet according to example 1: 18% of these people gave this tablet a rating of 9 to 10, 65% a rating of 6 to 8, meaning 83% gave it a rating of 6 or higher. Assessing the smell of the tablet according to example 2: 5% of these people gave this tablet a rating of 9 to 10, 76% a rating of 6 to 8, meaning 81% gave it a rating of 6 or higher. Taste assessment of the tablet according to example 1: 18% of these people gave this tablet a rating of 9 to 10, 65% a rating of 6 to 8, meaning 83% gave it a rating of 6 or higher. Taste assessment of the tablet according to example 2: 7% of these people gave this tablet a rating of 9 to 10, 40% a rating of 6 to 8, meaning 47% gave it a rating of 6 or higher. The immediate perceived effectiveness of tablet 1 in soothing the throat: 50% of people "agreed" or "strongly agreed" The immediate perceived effectiveness of tablet 2 in soothing the throat: 63% of people "agreed" or "strongly agreed" The immediate perceived effectiveness of tablet 2 for clearing the nose: 73% of people "agreed" or "strongly agreed"

Claims

DEMANDS 1. Combination product comprising, as active substances, at least zinc, eucalyptus or a bioequivalent compound of eucalyptus and erysimum or a bioequivalent compound of erysimum, poppy, propolis and vitamin C to help relieve symptoms associated with upper respiratory tract infections.

2. Combination product according to claim 1 characterized in that it is in the form of a single composition containing at least: -3 to 15%, preferably 6 to 10%, of dry eucalyptus extract -3 to 10%, preferably 4 to 8% dry extracts of erysimum -0.01 to 0.2%, preferably 0.05 to 0.1% zinc -0.01 to 2%, preferably 0.05 to 1% propolis -1 to 20%, preferably 5 to 10% vitamin C as a percentage by weight relative to the total weight of the composition in a physiologically acceptable medium.

3. Combination product according to any one of the preceding claims characterized in that the physiologically acceptable medium is suitable for oral administration.

4. Combination product according to any one of the preceding claims characterized in that it is in the form of a tablet.

5. Combination product according to any one of the preceding claims, characterized in that the eucalyptus, erysimum, and poppy are in the form of plant extracts 6. Combination product according to at least one of the preceding claims, for relieving the symptoms of subjects with an upper respiratory tract infection.